ValiRx plc

Our Pipeline

Default features description for sign up page.

Careers

Collaborative Pipeline

Board & Management Team

Privacy Policy

How we work

Strategy & Vision

Updates

Analyst Research

AIM Rule 26

Share Price Information

Reports, AGMs & Presentations

Regulatory News

Webinars

Partnering & Useful Links

Therapeutic Areas

Inaphaea Biolabs

Evaluation Pipeline

Home

Contact Us

DM Sans

Our priority areas of therapeutic focus are cancer and women’s health. We select only the most promising pre-clinical projects for progression through the drug development process, to become ready for clinical trials. We currently have a number of projects within our pipeline to target several conditions, such as triple-negative breast cancer, prostate cancer, endometriosis and adenocarcinoma. You can view our therapeutic areas and their associated drug development projects in greater detail 

Our development process for each molecule is specifically structured to minimise risk and maximise the chances of successful clinical development and approval for clinical use. Click on the molecules below to view their current progress and the relevant information, including clinical trial results, news items and presentations.

Alongside our product development portfolio, we also have projects within our evaluation pipeline. This pipeline process involves a rigorous scientific and commercial evaluation of a potential project, which enables us to determine if it is a good project to then become integrated within ValiRx's official project pipeline. For more information about our evaluation pipeline, its current prospects and their target therapeutic areas, click 

ValiRx accelerates scientific development and prepares the business infrastructure to present each SPV project as partnership ready.

With the necessary scientific and commercial preparation, projects are launched as a ValiRx Special Purpose Vehicle (SPV), presenting an opportunity for external funding and investment from partners, to continue progression into clinical development.

When the SPV is fledged and has independent financing, ValiRx will continue to provide all support necessary to deliver success. The income received from this is re-invested into the next generation of ValiRx preclinical projects. SPVs are valuable commercial entities, each positioned to strategically exit from ValiRx when the time is right.

For information about collaborations and partnerships please view our Partnering page.

Product portfolio pages